VINI News
VINI News — Veritas In News & Inquiry Veritas, Inquiry, News & Intelligence

Verified source report

STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug

CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

Source-feed image associated with STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
Source-feed image associated with the linked report: STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug.Credit: STAT Source-feed thumbnail displayed with attribution and outbound source link; VINI does not claim ownership or republish the third-party article body. Image source Cached source-feed image shown for continuity with attribution and an outbound source link; VINI does not claim third-party image authorship or republish the third-party article body.
Vinita Duniphin Science Source report

What happened

According to STAT’s source item, STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug, CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

Context

The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-05-30T13:25:26+00:00.

What to watch

Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.

Source

Primary source: STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug via STAT. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.

This source-cited VINI report links to the original publisher record. VINI does not republish third-party article bodies without rights clearance. 1 source listed.

Source links

Reader comments

Moderated discussion

Account access

Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.

Loading comments.